Open-label extension of a phase II trial in 24 adults with moderate-to-severe dermatomyositis: dazukibart 600 mg had no treatment-related serious adverse events or discontinuations through 92 weeks (7% of events severe); secondary skin activity scores improved.
RCTn = 24
Vleugels et al. Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies